Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 19;13(16):4892.
doi: 10.3390/jcm13164892.

The Clinicopathological Characteristics and Surgical Treatment of Gastrointestinal Neuroendocrine Neoplasm-A 10-Year Single-Center Experience

Michał Serafin  1 , Beata Jabłońska  2 , Emila Senderek  1 , Karolina Majewska  2 , Sławomir Mrowiec  2
Affiliations

The Clinicopathological Characteristics and Surgical Treatment of Gastrointestinal Neuroendocrine Neoplasm-A 10-Year Single-Center Experience

Michał Serafin et al. J Clin Med. .

Abstract

Background: Gastrointestinal neuroendocrine neoplasms (GI-NENs) represent a diverse group of tumors, with surgical resection being the gold standard for treatment. Materials and Methods: A retrospective analysis was conducted on 63 patients (32 women, 31 men) who underwent surgery for GI-NENs at the Department of Digestive Tract Surgery from January 2013 to June 2023. Tumors were classified by stage (localized, regionally advanced, metastatic). Results: Clinical symptoms were reported by 42 (66.7%) patients, with abdominal pain being the most common symptom, affecting 28 (44.4%) patients. The majority of tumors (44, 69.8%) originated in the midgut. The most frequently performed surgery was right hemicolectomy, carried out on 33 (52.4%) patients. Radical tumor resection was performed in 35 (55.6%) patients. Postoperative complications occurred in 12 (19%) patients, with male gender identified as an independent predictive factor for complications (p = 0.04). Non-functioning tumors were more common (33, 52.4%), and most tumors were classified as grade 1 histopathologically (49, 77.8%). Distant metastases were present in 29 (46%) patients. The overall two-year survival rate was 94.9%, with a five-year survival rate also estimated at 94.9%. Conclusions: GI-NENs are often diagnosed at advanced stages, frequently with distant or lymph node metastases, and predominantly arise in the midgut. Despite low postoperative morbidity and mortality, male gender may be a predictor of postoperative complications. Overall, the prognosis for GI-NENs is favorable, reflected in high overall survival rates.

Keywords: gastrointestinal tract; neuroendocrine tumors; surgical treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Hormone and tumor marker levels depending on the tumor stage. (a) Serotonin (b) CEA (c) 5-HIAA (Statistica®, 13.3, StatSoft). Abbreviations: CEA: Carcino-embryonic antigen, 5HIAA: 5-Hydroxyindoleacetic acid.
Figure 1
Figure 1
Hormone and tumor marker levels depending on the tumor stage. (a) Serotonin (b) CEA (c) 5-HIAA (Statistica®, 13.3, StatSoft). Abbreviations: CEA: Carcino-embryonic antigen, 5HIAA: 5-Hydroxyindoleacetic acid.
Figure 2
Figure 2
(a) Overall survival rate of the series. (b) Overall survival depending on tumor stage (Statistica®, 13.3, StatSoft).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Ulla Rocha J.L., Salgado A., Sardina Ferreiro R., Catalina P.F., Gallardo E. Neuroendocrine Gastroenteropancreatic Tumors: Where Are We? Surg. Laparosc. Endosc. Percutan Tech. 2017;27:36–41. doi: 10.1097/SLE.0000000000000362. - DOI - PubMed
    1. Öberg K.E. Gastrointestinal neuroendocrine tumors. Ann. Oncol. 2010;21((Suppl. 7)):vii72–vii80. doi: 10.1093/annonc/mdq290. - DOI - PubMed
    1. Williams E.D., Sandler M. The classification of carcinoid tumours. Lancet. 1963;1:238–239. doi: 10.1016/S0140-6736(63)90951-6. - DOI - PubMed
    1. Das S., Dasari A. Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences? Curr. Oncol. Rep. 2021;23:43. doi: 10.1007/s11912-021-01029-7. - DOI - PMC - PubMed
    1. Dasari A., Shen C., Halperin D., Zhao B., Zhou S., Xu Y., Shih T., Yao J.C. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017;3:1335–1342. doi: 10.1001/jamaoncol.2017.0589. - DOI - PMC - PubMed

LinkOut - more resources